Business
BrainsWay Announces FDA Approval of Neurolief’s Proliv™Rx Neuromodulation System for Major Depressive Disorder (MDD)
BrainsWay’s strategic investment in Neurolief paved the way for the first and only FDA approved at-home neuromodulation device with Class III Premarket Approval labeling for MDD patients who failed one or more prior antidepressantsBURLINGTON, Mass. and JERUSALEM, Jan. 12, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive brain stimulation technologies, today announced that the U.S. Food and Drug Administration (F
About this update from Brainsway Ltd
[{"type":"image","alt":"BrainsWay","displaySize":"","headline":null,"caption":"BrainsWay","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":219,"url":"https://media.zenfs.com/en/globenewswire.com/c68c48f9a0ccb3343f1124cb0b8b7c2f"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/6QrLgY5gLW7VtP5hZFuKtg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTMwNztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/c68c48f9a0ccb3343f1124cb0b8b7c2f","width":300,"height":219}},"lazy":false},{"type":"text","content":"BrainsWay’s strategic investment in Neurolief paved the way for the first and only FDA approved at-home neuromodulation device with Class III Premarket Approval labeling for MDD patients who failed one or more prior antidepressants","length":231,"tagName":"p"},{"type":"text","content":"BURLINGTON, Mass. and JERUSALEM, Jan. 12, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive brain stimulation technologies, today announced that the U.S. Food and Drug Administration (FDA) has granted Premarket Approval (PMA) for Neurolief's Proliv™Rx system, a Class III device, as an adjunctive treatment for adult patients suffering from major depressive disorder (MDD) who have failed to achieve satisfactory improvement from at least one previous antidepressant medication, for use at home or in the clinic.","length":604,"tagName":"p"},{"type":"text","content":"This approval represents a significant regulatory milestone, making Proliv™Rx the first and only at-home neuromodulation treatment with FDA labeling applicable to treatment refractory MDD patients. The approval expands the clinical landscape beyond traditional in-clinic care and reflects growing regulatory recognition of advanced neuromodulation solutions designed for use in the home setting.","length":395,"tagName":"p"},{"type":"text","content":"“Our strategic investment in Neurolief, which includes an option to acquire Neurolief, positions us to both enhance our current value proposition to our existing market as well as potentially increase our total addressable market by enabling care for patients who may not be able to easily access the clinic. We are currently working on meaningful synergistic approaches that include the commercial and research infrastructures of both companies,” stated Hadar L...